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MaBACKGROUND Coronary microvascular dysfunction (CMD) is defined by diminished flow reserve. Functional and
structural CMD endotypes have recently been described, with normal and elevated minimal microvascular resistance,
respectively.
OBJECTIVES This study determined the mechanism of altered resting and maximal flow in CMD endotypes.
METHODS A total of 86 patients with angina but no obstructive coronary disease underwent coronary pressure and
flow measurement during rest, exercise, and adenosine-mediated hyperemia and were classified as the reference group or
as patients with CMD by a coronary flow reserve threshold of 2.5; functional or structural endotypes were distinguished
by a hyperemic microvascular resistance threshold of 2.5 mm Hg/cm/s. Endothelial function was assessed by forearm
blood flow (FBF) response to acetylcholine, and nitric oxide synthase (NOS) activity was defined as the inverse of FBF
reserve to NG-monomethyl-L-arginine.
RESULTS Of the 86 patients, 46 had CMD (28 functional, 18 structural), and 40 patients formed the reference group.
Resting coronary blood flow (CBF) (24.6  2.0 cm/s vs. 16.6  3.9 cm/s vs. 15.1  4.7 cm/s; p < 0.001) and NOS activity
(2.27  0.96 vs. 1.77  0.59 vs. 1.30  0.16; p < 0.001) were higher in the functional group compared with the structural
CMD and reference groups, respectively. The structural group had lower acetylcholine FBF augmentation than the
functional or reference group (2.1  1.8 vs. 4.1  1.7 vs. 4.5  2.0; p < 0.001). On exercise, oxygen demand was highest
(ratepressure product: 22,157  5,497 beats/min/mm Hg vs. 19,519  4,653 beats/min/mm Hg vs. 17,530  4,678
beats/min/mm Hg; p ¼ 0.004), but peak CBF was lowest in patients with structural CMD compared with the functional
and reference groups.
CONCLUSIONS Functional CMD is characterized by elevated resting flow that is linked to enhanced NOS activity.
Patients with structural CMD have endothelial dysfunction, which leads to diminished peak CBF augmentation and
increased demand during exercise. The value of pathophysiologically stratified therapy warrants investigation.
(J Am Coll Cardiol 2020;75:2538–49) © 2020 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).N 0735-1097 https://doi.org/10.1016/j.jacc.2020.03.051
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AB BR E V I A T I O N S
AND ACRONYM S
CBF = coronary blood flow
CFR = coronary flow reserve
CMD = coronary microvascular
dysfunction
eNOS = endothelial nitric
oxide synthase







NOS = nitric oxide synthase
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2539O ne-half of all patients with angina referredfor angiography have nonobstructive coro-nary artery disease (NOCAD); those with
coronary microvascular dysfunction (CMD) exhibit a
poorer prognosis (1,2). CMD is diagnosed when there
is diminished flow augmentation in response to a
pharmacological vasodilator or reduced coronary
flow reserve (CFR). A CFR <2.5 is associated with
abnormal coronary flow with exercise and inducible
ischemia on perfusion cardiac magnetic resonance
imaging. We recently described 2 endotypes of CMD
with distinct processes that contributed to low CFR:
patients with functional CMD who have increased
baseline flow (due to reduced microvascular resis-
tance at rest); and patients with structural CMD who
have reduced hyperemic flow (due to high minimal
microvascular resistance) (3). Resting coronary blood
flow (CBF) is regulated by nitric oxide synthase (NOS)
and its role in the coronary circulation has been
extrapolated from effects of vasoactive medication
within the forearm circulation (4,5). In healthy pa-
tients, physical exercise involves synergistic adapta-
tions between the peripheral and coronary
vasculature to match CBF supply with myocardial ox-
ygen demand, a process that is disrupted in structural
CMD (3,6). The endothelium is responsible for trans-
lating mechanical forces (or shear stress) to smooth
muscle dilatation in the coronary circulation and
may have a similar role systemically during exercise
(6). We sought to unravel the pathobiology of the 2
endotypes and hypothesized that: 1) elevated resting
blood flow in functional CMD is a response to
increased demand and is mediated by increased ac-
tivity of the NOS pathway; and 2) structural CMD is
reflective of a generalized disorder of vascular dilata-
tion that affects peak flow in response to stress.SEE PAGE 2550METHODS
Patients who underwent elective diagnostic angiog-
raphy for investigation of exertional chest pain were
enrolled in the study. Inclusion criteria were pre-
served left ventricular systolic function (ejection
fraction >50%) and unobstructed coronary arteries
(<30% diameter stenosis and/or fractional flow
reserve >0.80). Exclusion criteria were intolerance to
adenosine, chronic kidney disease (estimated
glomerular filtration rate <30 ml/min/1.73 m2),
concomitant valve disease (greater than mild on
echocardiography), cardiomyopathy, or any neuro-
muscular comorbidity that could affect ability to
perform bicycle exercise. Antianginal medications
were stopped, and patients abstained from caffeine24 h before all study visits. Antihypertensive
medications were continued to ensure study
participants were close to normotensive
before study visits. The study protocol was
approved by the UK National Research Ethics
Service (17/LO/0203). The study was regis-
tered with the National Institute for Health
Research UK Clinical Research Network
portfolio database (Central Portfolio Man-
agement System identifier: 33170).
CATHETERIZATION PROTOCOL. Catheteri-
zation was performed via the right radial ar-
tery using standard coronary catheters. All
patients received 1 mg intravenous mid-
azolam, 1 mg isosorbide dinitrate via the
radial sheath, and intra-arterial unfractio-
nated heparin (70 U/kg) before intracoronary physi-
ological measurements. A dual pressure and Doppler
sensor-tipped 0.014-inch intracoronary wire (Com-
bowire, Volcano Philips, San Diego, California) was
used to measure coronary pressure and flow velocity
in the left anterior descending artery, as previously
described (3,7). Hemodynamic measurements were
recorded under resting conditions, during intravenous
adenosinemediated hyperemia (140 mg/kg/min)
and continuously during bicycle exercise, using a
specially adapted supine ergometer (Ergosana, Bitz,
Germany) attached to the catheter laboratory table.
Exercise began at a workload of 30 W and increased
every 2 min by 20 W. When muscle weakness
restricted increasing workloads, resistance was fixed
at the maximum tolerated level, and exercise
continued until exhaustion.
ANALYSIS OF CORONARY PHYSIOLOGICAL DATA. Signals
were sampled at 200 Hz, with data exported into a
custom-made study manager program (Academic
Medical Centre, University of Amsterdam, Amster-
dam, the Netherlands). Pan-cardiac cycle analysis and
coronary wave intensity analysis were performed on
custom-made software, Cardiac Waves (Kings College
London, London, United Kingdom) as previously
described (3,7). Microvascular resistance was calcu-
lated as the ratio of the distal mean coronary pressure
and the average peak velocity. The supply/demand
ratio was estimated as the average peak velocity/
ratepressure product (a measure of external stroke
work) and denoted as supply/demandEXT. By wave
intensity analysis, 4 dominant waves were identified
and included in our analysis: 1) the backward
compression wave, which causes flow deceleration
during isovolumetric contraction in early systole;
2) the forward compression wave, which causes flow
acceleration that is associated with peak aortic
FIGURE 1 Final Studies Undertaken







All patients with angina and no obstructive coronary disease
(NOCAD) enrolled in the study had assessment of coronary
flow reserve (n ¼ 86). Cath Lab Exercise ¼ invasive catheter
laboratory exercise physiology; Vascular Study ¼ forearm
venous occlusion plethysmography.
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2540pressure; 3) the forward expansion wave, which
causes flow deceleration associated with the fall in
aortic pressure in late systole; and 4) the backward
expansion wave, which causes flow acceleration
during isovolumetric relaxation in early diastole.
Total wave intensity was calculated as the sum of the
area under the curve of the 4 principal waves, and
coronary perfusion efficiency was calculated as the
percentage of accelerating wave intensity in relation
to total wave intensity.
Patients were classified into the reference group
(CFR $2.5), functional CMD group (CFR <2.5; hyper-
emic microvascular resistance [hMR] <2.5 mm Hg/cm/s),
or structural CMD group (CFR <2.5; hMR
$2.5 mm Hg/cm/s) (3).
VENOUS OCCLUSION PLETHYSMOGRAPHY. Forearm
blood flow (FBF) was measured by venous occlusion
plethysmography (Hokanson, Bellevue, Washington)
as previously described (8). The right brachial artery
was cannulated with a 27-gauge needle under local
anesthetic cover with 1% lidocaine and saline vehicle
or drugs infused at 1 ml/min. Saline was infused to
establish a baseline before infusion of acetylcholine
(Bausch & Lomb, Kingston-upon-Thames, United
Kingdom) at 7.5 and 15 mg/min, adenosine (Sanofi,
Guildford, United Kingdom) at 125 and 250 mg/min,
and the nonselective NOS inhibitor, NG-monomethyl-
L-arginine (L-NMMA) (Bachem, Rhein, Germany) at 2
and 4 mmol/min. Each vasoactive agent was infused at
2 doses for 6 min each, with FBF recorded over the
last 3 min of each infusion (ml/min/100 ml forearm
volume). The effect of each agent was calculated as
the ratio of FBF compared with the preceding saline
baseline. NOS activity was defined as the inverse of
FBF reserve to L-NMMA.
CARDIAC BIOMARKERS AND MECHANICAL FUNCTION.
N-terminal probrain natriuretic peptide levels were
measured before angiography using conventional
clinical assays. Diastolic function was assessed using
standard transthoracic echocardiography measure-
ments (9). Subjects also underwent high resolution
cardiac magnetic resonance imaging with stress
perfusion; these data were already presented in more
detail (3). All scans were performed on a dedicated
3-T cardiac magnetic resonance scanner (Achieva TX,
Phillips Healthcare, Best, the Netherlands). Contig-
uous short-axis slices were acquired from the base to
the apex for calculation of left ventricular function
and mass (CVI42, v5.1.1, Circle Cardiovascular Imag-
ing, Calgary, Ontario, Canada).
STATISTICAL ANALYSES. Sample size was estimated
on the basis of the coprimary endpoints of FBF
response to L-NMMA and acetylcholine. Fromprevious reports, the expected FBF response in the
reference group to L-NMMA and acetylcholine was
0.62  0.03 and 4.1  0.9, respectively (10). Assuming
an allocation ratio among the reference group/func-
tional/structural of 2:1:1, 56 patients would provide
95% power to detect a 10% difference in response to
L-NMMA and 80% power to detect a 20% difference in
response to acetylcholine. A total study sample of 85
was planned for powering both the exercise physi-
ology study and FBF study, assuming 70% to 80%
patients would undergo each study (3). Statistical
analysis was performed using SPSS version 24 (IBM
Corp., Armonk, New York). Normality of data was
visually assessed (using histograms and the normal
Q-Q plot) using the Shapiro-Wilk test. Continuous
normal data are expressed as mean  SD and
compared using paired Student’s t-tests. Non-normal
data are expressed as median (interquartile range
[IQR]) and compared using the Mann-Whitney U test.
Categorical variables are compared with chi-square
tests. Repeated-measures analysis of variance of
both drug doses was used to evaluate effects on FBF,
whereas FBF in response to each agent was averaged
out across low and high doses for the purposes of
numerically displaying results among the study
groups. A 2-tailed test for significance was performed
for all analyses; p < 0.05 was considered statistically
significant. The p values and 95% confidence in-
tervals presented in this study were not adjusted for
multiplicity; therefore, inferences drawn from these
statistics might not be reproducible.






(n ¼ 18) p Value
Clinical characteristics
Age, yrs 57  10 57  12 57  9 0.99
Female 27 (68) 25 (89) 15 (83) 0.51
Hypertension 25 (63) 12 (43) 14 (78) 0.03
Diabetes 9 (23) 5 (18) 8 (44) 0.04
No. of antianginal Rx 0.88  0.85 0.89  0.92 0.59  0.51 0.31
No. of antihypertensive Rx 0.50  0.60 0.46  0.74 1.00  1.00 0.05
Cardiac biomarkers and function
NT-proBNP, pg/ml 34 (22–90) 69 (32–116) 132 (82–179) 0.01
Echo, E/é 6.9  2.2 7.5  3.0 8.4  2.3 0.39
Indexed LV mass, g 44.6  16.9 42.9  12.1 42.8  10.4 0.99
LVEF, % 64.8  5.3 67.4  6.8 66.0  4.0 0.53
Exercise performance
Exercise time, s 417  146 412  117 364  93 0.21
Exercise work, W 72  28 65  21 61  33 0.65
Values are mean  SD, n (%), or median (interquartile range). Risk factors include those with an established diagnosis who required treatment with prescription therapy (Rx).
p value refers to the difference between functional and structural microvascular dysfunction (coronary microvascular dysfunction [CMD]) groups.
LV ¼ left ventricular; LVEF ¼ left ventricular ejection fraction; NT-proBNP ¼ N-terminal pro–brain natriuretic peptide; Rx ¼ prescriptions.
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2541RESULTS
A total of 86 patients with angina and NOCAD un-
derwent coronary microvascular function testing;
they were enrolled into the study and subsequently
classified into the reference group (n ¼ 40), the
functional CMD (n ¼ 28) group, and the structural
CMD (n ¼ 18) group using the preceding pre-specified
definition. Seventy-five patients underwent catheter
laboratory exercise, and 59 patients underwent pe-
ripheral vascular function testing (Figure 1). Patients
with structural CMD had higher incidences of hyper-
tension and diabetes compared with patients in the
functional CMD and reference groups (78% vs. 43%
vs. 63%; p ¼ 0.03; and 44% vs. 18% vs. 23%; p ¼ 0.04).
Patients with structural CMD were taking a greater
number of antihypertensive agents (1.00  1.00 vs.
0.46  0.74; p ¼ 0.046) but a similar number of
anti-anginal medications. N-terminal probrain
natriuretic peptide values were highest in patients
with structural CMD compared with those with
functional CMD and reference group patients (132 pg/
ml [IQR: 82 to 179 pg/ml] vs. 69 pg/ml [IQR: 32 to 116
pg/ml] vs. 34 pg/ml [IQR: 22 to 90 pg/ml]). Overall
diastolic function and exercise time and external
work were no different between both CMD endotypes
(Table 1).
RESTING PHYSIOLOGY. Resting CBF was higher
among patients with functional CMD compared with
patients with structural CMD and reference group
patients (24.6  5.7 cm/s vs. 16.6  3.9 cm/s vs. 15.2 
4.7 cm/s; p < 0.001 for both). Resting myocardialblood flow on cardiac magnetic resonance imaging
had a similar pattern among the groups (1.42  0.40
ml/min/g vs. 1.23  0.27 ml/min/g vs. 1.13  0.21
ml/min/g; p ¼ 0.21 vs. structural and p ¼ 0.003 vs.
reference group patients). Patients with functional
and structural CMD had higher total resting
wave energy than reference group patients (1.71  1.2
Wcm2s2 vs. 1.46  0.6 Wcm2s2 vs. 0.9  0.8
Wcm2s2; p ¼ 0.01 and 0.001). Despite this, overall
coronary perfusion efficacy was similar between the
groups (59  12% vs. 60  12% vs. 63  11%; p ¼ 0.69
and p ¼ 0.22).
Supply/demandEXT was higher in patients with
functional CMD than those with structural CMD
and in reference group patients (13.5  3.2 cm/mm
Hg  102 vs. 8.2  2.0 cm/mm Hg  102 vs. 9.1 
3.4 cm/mm Hg  102; both p < 0.001).
The reduction in FBF in response to L-NMMA was
greatest in patients with functional CMD compared
with those with structural CMD and reference group
patients (flow reserve: 0.49  0.13 vs. 0.61  0.14 vs.
0.79  0.09; p ¼ 0.01). NOS activity was highest in
patients with functional CMD compared with those
with structural CMD and reference group patients
(2.27  0.96 vs. 1.77  0.59 vs. 1.30  0.16; p < 0.001
both). The determinants and patterns of resting
physiology are summarized in Figure 2.
RESPONSE TO EXERCISE AND VASOACTIVE
AGENTS. Although functional and structural CMD
had similar CFRs (1.98  0.33 vs. 1.96  0.38;
p ¼ 0.82), the former had abnormally high resting
flow and the latter had diminished peak flow. By

















































Total Wave Energy 0.9 ± 0.8 1.71 ± 1.2 1.46 ± 0.6


































Supply/DemandEXT 9.1 ± 3.4 13.5 ± 3.2 8.2 ± 2.0
(Top) Patients with functional coronary microvascular dysfunction (CMD) have higher supply/demandEXT (average peak velocity/ratepressure
product, in cm/mm Hg  102) than structural CMD and reference group patients. (Middle) Both functional and structural CMD have elevated
nitric oxide synthase (NOS) activity calculated as resting forearm blood flow/forearm blood flow during infusion of NG-monomethyl-L-arginine.
(Bottom) Both functional and structural CMD have increased resting wave energy calculated using wave intensity analysis. *Statistically
significant different from reference group, where p < 0.05. Numbers depict mean values and error bars depict SD. BCW ¼ backward
compression wave; BEW ¼ backward expansion wave; FCW ¼ forward compression wave; FEW ¼ forward expansion wave.
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*Significant difference from reference group. †Significant difference between CMD endotypes, both p < 0.05. Numbers depict mean values
and error bars depict SD. Abbreviations as in Figure 2.
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2543definition, coronary microvascular resistance during
peak exercise was higher in patients with structural
CMD compared with those with functional CMD and
reference group patients (3.1  1.8 mm Hg/cm/s vs. 1.9
 0.4 mm Hg/cm/s vs. 2.1  0.5 mm Hg/cm/s;
p < 0.001 structural compared with both). CBF during
peak exercise was lower in patients with structural
CMD compared with those with functional CMD (25 
5 cm/s vs. 34  11 cm/s; p < 0.001) and similar to that
in reference group patients (27  8 cm/s; p ¼ 0.41).
During exercise, the magnitude of all waves increased
in all subjects, but accelerating wave energy
increased preferentially in reference group patients,
whereas decelerating energy increased in both CMD
groups. Perfusion efficiency was lower in both pa-
tients with structural CMD and functional CMDcompared with patients in the reference group (41 
10% vs. 46  9% vs. 65  15%) (Figure 3).
In terms of systemic hemodynamics, during peak
exercise, the structural group had higher systolic
blood pressure (188  25 mm Hg) than the functional
(161  27 mm Hg; p ¼ 0.004) and reference group pa-
tients (156  30 mm Hg; p < 0.001), and consequently,
had a higher ratepressure product (22,157  5,497
beats/min/mmHg vs. 19,519 4,653 beats/min/mmHg
vs. 17,530  4,678 beats/min/mm Hg; p ¼ 0.12 vs.
the functional group and p ¼ 0.004 vs. the reference
group) (Figure 4).
The response to vasoactive agents was also signif-
icantly different across the groups. The increase in
FBF in response to acetylcholine was diminished in
the structural group compared with the functional




























































































































Structural CMD (n = 34) Functional CMD (n = 24) Reference Group (n = 17)
Patients with structural CMD had varying hemodynamic responses to supine bicycle exercise and adenosine-induced hyperemia compared with those with
functional CMD and those in the reference group. Numbers depict mean values. 1 min ¼ after 1 min of exercise; 50% ¼ 50% of maximal exercise time;
hyperemia ¼ adenosine-induced hyperemia; MR ¼ microvascular resistance; peak ¼ immediately before exercise was discontinued due to exhaustion;
RPP ¼ ratepressure product.
Rahman et al. J A C C V O L . 7 5 , N O . 2 0 , 2 0 2 0
Physiological Stratification of Microvascular Dysfunction M A Y 2 6 , 2 0 2 0 : 2 5 3 8 – 4 9
2544and reference group patients (2.1  1.8 vs. 4.1  1.7 vs.
4.5  2.0; p ¼ 0.001 vs. the functional group and
p ¼ 0.0006 vs. the reference group) and was dimin-
ished in response to adenosine (3.8  1.8 vs. 4.8  2.8
vs. 4.7  1.7; p ¼ 0.04 vs. the functional group and
p ¼ 0.03 vs. the reference group) (Figure 5). There
were no differences in FBF vasodilatory response to
acetylcholine or adenosine between reference group
patients and patients with functional CMD (p ¼ 0.46and p ¼ 0.90, respectively). These results are sum-
marized in the Central Illustration.
DISCUSSION
This study showed that functional and structural
CMD endotypes have inefficient cardiac-coronary
coupling during exercise compared with reference
group patients with preserved CFR. This was





















































































































Structural CMD (n = 14) Functional CMD (n = 22) Reference Group (n = 23)
Both functional and structural CMD demonstrate greater vasoconstriction in response to NG-monomethyl-L-arginine (L-NMMA), whereas structural CMD also
demonstrated reduced vasodilatation to acetylcholine (ACh) and adenosine (Ado). Numbers depict mean values.
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2545congruent with our previous demonstration of higher
rates of inducible myocardial ischemia during vaso-
dilator stress (3). Although both CMD endotypes
display generalized disorders of the circulation, the
underlying pathophysiological determinants are
distinct. In functional CMD, there is increased
myocardial perfusion at rest, which is partly
explained by increased external cardiac work but may
also be due to greater potential energy at rest, which
may, in turn, be explained by the higher wave energy
at rest. Increased perfusion appears to be mediated by
enhanced NOS activity, which leads to submaximal
coronary vasodilatation at rest, which, in turn, re-
duces the vasodilator reserve in response to stress.
Structural CMD had similar resting microvascular
resistance to reference group subjects at rest but had
markedly elevated microvascular resistance during
both exercise and vasodilator stress, which led to
maladaptive exercise physiology and global myocar-
dial ischemia, respectively. In addition, the structural
group had impaired peripheral endothelium-
dependent dilatation and exaggerated exercise hy-
pertension, which caused increased afterload and
increased myocardial oxygen demand, which exac-
erbated the supply deficit. The resting pathophysi-
ology in both endotypes of CMD might benefit from
metabolic modulation, whereas structural CMD might
also derive benefit from therapies designed to reduceafterload and myocardial oxygen demand during
effort.
STRUCTURAL CMD. The historical perception of CMD
was that it was related to high vascular resistance
during increased demand or vasodilatation. Interest-
ingly, in our study cohort, the patients who con-
formed to this pathophysiological subtype (whom we
classified as having structural CMD) represented less
than one-half of all patients with impaired CFR. The
structural CMD group had more established cardio-
vascular risk factors and poorly controlled hyperten-
sion, a process similarly associated with diminished
maximal flow (11). Exercise-induced hypertension led
to increased myocardial oxygen demand during ex-
ercise within this group. Attenuated reduction in
afterload with exercise interrupted the usual syner-
gistic response of the coronary and peripheral circu-
lations and predispose patients to ischemia (6).
Systemic vasodilatation in response to acetylcholine,
which in health generates endogenous nitric oxide
via endothelial nitric oxide synthase (eNOS), was
impaired in patients with structural CMD. Therefore,
shear stress during exercise might not translate to
appropriate eNOS-mediated dilatation of coronary
and peripheral vascular smooth muscle, which could
lead to enhanced vascular tone in both beds. Shear
stressmediated increases in resting CBF are believed
CENTRAL ILLUSTRATION Coronary Microvascular Dysfunction Disease Endotypes
Rahman, H. et al. J Am Coll Cardiol. 2020;75(20):2538–49.
Summary of distinct coronary, myocardium, and systemic changes associated with each disease endotype compared with the reference group of patients (3).
CMD ¼ coronary microvascular dysfunction; NT-proBNP ¼ N-terminal pro–brain natriuretic peptide.
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2546to be protective, and it has been suggested this
mechanism might be defective in patients with dia-
betes, which could involve the eNOS pathway. Ge-
netic polymorphisms involving eNOS dysfunction
have been implicated in CMD; whether genotyping
individuals might have a role in classifying the dis-
ease state and in guiding therapy is a further exciting
future prospect (12).
Patients with NOCAD with elevated hyperemic
resistance have a higher incidence of refractory
angina. Our study similarly identified a numerical
trend toward a higher burden of inducible myocardial
ischemia and biomarker changes that suggested that
structural CMD was a more advance disease endotype
(3,13). The impaired augmentation of the diastolic
acceleratory wave suggested impaired lusitropy,
whereas elevated N-terminal probrain natriuretic
peptide levels suggested an early diastolic dysfunc-
tion state (14). Whether elevated resting flow in
functional CMD precede changes that lead to struc-
tural CMD needs to be assessed with longitudinal
studies. A similar bimodal pattern of impaired flow
reserve was observed in the diabetic coronary circu-
lation (15). Studies that dichotomized patients with
CMD based upon maximal flow demonstrated that
mortality rate was higher in structural CMD, whereasmajor adverse cardiovascular events were higher in
functional CMD compared with those with isolated
endothelial dysfunction, which supported this notion
of disease progression identified by measuring mini-
mal microvascular resistance (16). The state of raised
minimal microvascular resistance in structural CMD
might be surmountable over time with appropriate
treatment; therefore, the term structural should not
be considered to imply an irreversible disease pro-
cess. In the first instance, judicious blood pressure
control using large vessel vasodilators could enhance
the normal synergistic adaptation to exercise
observed in health in structural CMD. Endothelial
function modulation, including pleiotropic actions of
statins, might theoretically exert a greater effect on
structural CMD compared with functional CMD clas-
ses and need to be studied in a placebo randomized
study.
FUNCTIONAL CMD. Although defined by demon-
strating normal minimal microvascular resistance,
the pathophysiological hallmark of functional CMD is
increased resting flow. This was previously described
and was associated with greater risk of major adverse
cardiovascular events (17). Coronary autoregulation is
the intrinsic capacity of microcirculation to maintain
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perfusion pressures, and elevated flow can represent
either disordered autoregulation or appropriate
autoregulation in the face of increased myocardial
oxygen demand. Our study provided indirect evi-
dence in favor of the latter and also suggested that
elevated resting coronary flow might be mediated by
elevation of NOS activity. Alternatively, it was
possible that increased nitric oxide activity was an
adaptation to abnormally increased vasoconstrictor
responsivity. For instance, patients with microvas-
cular angina were shown to exhibit a greater con-
tractile response to endothelin-1 (18). A study of
patients with the historical cardiac syndrome X defi-
nition demonstrated accentuated responsivity
following in vivo administration of endothelin-A
antagonism, and modulation of this pathway is
currently being studied as a novel therapeutic target
in CMD (10,19). Although we measured the effect of
NOS inhibition in the peripheral vascular bed, good
correlation between the coronary vascular bed was
previously demonstrated (4). Nitric oxide dilatation
of proximal arteries occurs preferentially to preserve
vasodilator reserve in the distal arterioles; therefore,
this may serve as an initially protective mechanism to
maintain metabolic vasodilatory reserve (20,21).
Although external myocardial work in the form of
ratepressure product is not elevated in functional
CMD, higher basal metabolic requirements can un-
derlie elevated resting CBF (22). Higher resting wave
energy, but no net increment in perfusion efficiency
implies an inefficient resting state more pronounced
in functional than structural CMD. An inefficient
metabolic state may represent the “common soil” of
CMD and heart failure with preserved ejection frac-
tion (23). In patients with diabetes, depressed
myocardial energetics precedes any overt changes in
microvascular function; similarly, diastolic dysfunc-
tion occurs late within the disease natural history
(24,25). In heart failure with preserved ejection frac-
tion, reduced CFR is attributable to both elevated
resting CBF and diminished hyperemic CBF, resem-
bling both functional and structural CMD endotypes;
emerging data increasingly suggest that CMD may be
a pathological precursor of heart failure with pre-
served ejection fraction (26,27).
PERSONALIZED THERAPY. Numerous pharmacolog-
ical and non-pharmacological therapies have been
studied in patients with chest pain and NOCAD.
However, previous studies have been limited by
enrolling small numbers of participants with variable
inclusion criteria, using differing diagnostic test
thresholds and measuring dissimilar endpoints(28,29). With an increased armamentarium of novel
therapies, such as immunomodulation for treatment
of atherosclerotic coronary artery disease, there is a
movement toward stratifying populations to deter-
mine who will derive the greatest benefit (30). The
migration from empirically treating NOCAD to iden-
tifying CMD has already demonstrated superiority,
and it is likely the heterogeneous population of pa-
tients with CMD can be further refined (31).
Measuring resistance is relatively easy to do, and the
resistance indexes (either Doppler-based hMR or the
thermodilution-based index of microvascular resis-
tance) are automatically calculated when deter-
mining CFR using currently available pressure
sensor-tipped guide wires such as the Combowire
(Volcano Philips) or Pressure Wire X (Abbott, Chicago,
Illinois) (32,33). In combination with CFR, hMR or
index of microvascular resistance measurement
would distinguish the 2 distinct CMD endotypes with
different dysfunctional pathways leading to exercise
ischemia. Identifying patients with CMD and coro-
nary vasospasm has already been a huge step forward
in terms of personalizing therapy for NOCAD (31,34).
CorMicA investigators have similarly stratified pa-
tients based upon CFR, index of microvascular resis-
tance, and vasospastic abnormalities, demonstrating
differences in peripheral endothelin-1 function
among endotypes, paving the way for repurposing of
targeted pharmacotherapy (18). Placebo-controlled
trials will be the next step to identifying if targeted
therapy based upon CMD endotypes will yield supe-
rior outcomes to empirical treatment of all-comers
with diminished CFR. Understanding the mecha-
nistic basis of CMD endotypes may guide the devel-
opment of novel therapies and improve our
management of this common yet poorly
treated condition.
STUDY LIMITATIONS. This was a mechanistic single-
center study with relatively small numbers of pa-
tients in each group. Our study design did not
distinguish whether nNOS or eNOS or both were
upregulated in both CMD endotypes and whether the
findings in the forearm truly mimicked those within
the coronary circulation. This was an observational
study, and it was unclear if this classification could
guide therapeutics to sufficiently improve patient
outcome. This will need to be assessed in a placebo
randomized trial. Invasive CFR is currently the most
accepted method for classifying CMD in patients with
NOCAD. Like all biological measurements, CFR is a
continuous variable, and, for this study, a dichoto-
mous CFR threshold of 2.5 was adopted to define
CMD, acknowledging that a lower threshold might
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Measurement of microvascular resistance at rest and
during pharmacologically induced hyperemia iden-
tifies 2 types of coronary microvascular dysfunction.
In one endotype, CBF is impaired at rest due to nitric
oxide dysregulation, whereas in the other, endothelial
dysfunction limits peak hyperemic blood flow.
TRANSLATIONAL OUTLOOK: Therapeutic studies
should stratify patients with microvascular dysfunc-
tion based on impairment of resting or hyperemic
flow.
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2548have had enhanced specificity at the cost of sensi-
tivity. Moreover, because our reference group were
not healthy volunteers but had symptoms that led to
angiography, adopting a 2.5 threshold ensured that
their endothelium-independent microvascular func-
tion was truly normal. Patients in the reference group
might have had occult coronary abnormalities, such
as endothelial dysfunction or coronary vasospasm,
that could be unmasked during provocation testing.
During cardiac catheterization, pre-medication using
radial nitrates were necessary to enable bike exercise
via this protocol. Although the same dose was
administered to each study participant, this might
have affected the coronary physiology results. How-
ever, with most angiography being performed radi-
ally, this method was more representative of
contemporary practice.
CONCLUSIONS
CMD is associated with systemic vascular endothelial
abnormalities. Functional and structural endotypes,
defined by reduced resting and high minimal micro-
vascular resistance, respectively, have different
mechanisms of ischemia during exercise. In func-
tional CMD, inefficient cardiac-coronary coupling
during peak exercise and during rest leads to higher
myocardial oxygen demand in the face of sub-
maximally exhausted vasodilatory reserve at rest. Instructural CMD, systemic endothelium dilatory func-
tion leads to systemic hypertension and increased
myocardial work, whereas coronary blood flow
augmentation is diminished. This is further com-
pounded by an inefficient cardiac-coronary coupling
state.
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